Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

PURPOSE: We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-α-2a) in patients with essential thrombocythemia (ET) and polycythemia vera (PV). PATIENTS AND METHODS: Seventy-nine patients (40 with PV and 39 with ET) have been treated. Median time from diagnosis to PEG-IFN-α-2a was...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Quintás-Cardama, Alfonso, Kantarjian, Hagop, Manshouri, Taghi, Luthra, Rajyalakshmi, Estrov, Zeev, Pierce, Sherry, Richie, Mary Ann, Borthakur, Gautam, Konopleva, Marina, Cortes, Jorge, Verstovsek, Srdan
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2009
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4881362/
https://ncbi.nlm.nih.gov/pubmed/19826111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.6075
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires